Stephen F. Betz - 15 Oct 2021 Form 3 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role: Chief Scientific Officer
Signature: /s/ Marc Wilson, as attorney-in-fact
Issuer symbol: CRNX
Transactions as of: 15 Oct 2021
Net transactions value: $0
Form type: 3
Filing time: 19 Oct 2021, 16:54:20 UTC
Next filing: 25 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	CRNX	Common Stock						187,925	15 Oct 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CRNX	Stock Option (right to buy)							15 Oct 2021	Common Stock	182,370	$1.91	Direct	F1
holding	CRNX	Stock Option (right to buy)							15 Oct 2021	Common Stock	91,185	$9.28	Direct	F2
holding	CRNX	Stock Option (right to buy)							15 Oct 2021	Common Stock	56,250	$25.19	Direct	F3
holding	CRNX	Stock Option (right to buy)							15 Oct 2021	Common Stock	60,000	$22.61	Direct	F4
holding	CRNX	Stock Option (right to buy)							15 Oct 2021	Common Stock	85,000	$15.29	Direct	F5
holding	CRNX	Stock Option (right to buy)							15 Oct 2021	Common Stock	15,000	$23.19	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. The shares subject to the option are also subject to accelerated vesting as set forth in the employment agreement between the Issuer and the Reporting Person.
F2	1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date; provided, however, that one-half of the shares subject to the option are subject to the further condition that they may not be exercised until the occurrence of the Issuer's initial public offering and, in the event the Issuer's initial public offering does not occur prior to the first anniversary of May 25, 2018, such portion of the stock options shall be automatically forfeited. The shares subject to the option are also subject to accelerated vesting as set forth in the employment agreement between the Issuer and the Reporting Person.
F3	The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement Date of March 8, 2019.
F4	The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 24, 2020.
F5	The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 26, 2021.
F6	The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of September 1, 2021.